01635nas a2200325   4500000000100000008004100001100001900042700001800061700002100079700001500100700002100115700001900136700001700155700002000172700001900192700001800211700001600229700001800245700001800263700001500281700001700296700001500313700001600328700001600344245011900360300001200479490000700491520079700498022001401295       2018                            d1 aJha Vivekanand1 aJadoul Michel1 aBerenguer Marina1 aDoss Wahid1 aFabrizi Fabrizio1 aIzopet Jacques1 aKamar Nassim1 aKasiske Bertram1 aLai Ching-Lung1 aMorales José1 aPatel Priti1 aPol Stanislas1 aSilva Marcelo1 aBalk Ethan1 aGordon Craig1 aEarley Amy1 aDi Mengyang1 aMartin Paul00aExecutive summary of the 2018 KDIGO Hepatitis C in CKD Guideline: welcoming advances in evaluation and management.  a663-6730 v943 a<p>
Infection with the hepatitis C virus (HCV) has adverse liver, kidney, and cardiovascular consequences in patients with chronic kidney disease (CKD), including those on dialysis therapy and in those with a kidney transplant. Since the publication of the original Kidney Disease: Improving Global Outcomes (KDIGO) HCV Guideline in 2008, major advances in HCV management, particularly with the advent of direct-acting antiviral therapies, have now made the cure of HCV possible in CKD patients. In addition, diagnostic techniques have evolved to enable the noninvasive diagnosis of liver fibrosis. Therefore, the Work Group undertook a comprehensive review and update of the KDIGO HCV in CKD Guideline. This Executive Summary highlights key aspects of the guideline recommendations.
</p>
  a1523-1755